Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent
experimental and clinical evidence suggests synergy between radiation therapy and
immunotherapy. The investigators will explore this synergy with a feasibility study of 26
patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90
selective internal hepatic radiation followed by immunotherapy with the combination of
ipilimumab and nivolumab.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
David Minor, MD
Collaborators:
California Pacific Medical Center Jefferson Medical College of Thomas Jefferson University University of Chicago